Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis — Stella

Home/Relapsing Remitting Multiple Sclerosis/Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

View on ClinicalTrials.gov

Recruiting

Back to Relapsing Remitting Multiple Sclerosis trials

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

Trial locations(1 site)

Norway

Haukeland University Hospital, Deparment of medical biochemistry and pharmacology, Bergen, Vestland

Key details

Sponsor

Haukeland University Hospital

Collaborators

University of Bergen

Enrollment target

~60 participants

Started

March 2021

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 60 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.